Michael Mooney

Aphton Corp. operates as a biopharmaceutical company, which is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and gastrointestinal disease. The company was founded on May 12, 1981 and is headquartered in Philadelphia, PA.

Founded in 1999 by the late Thomas Watson, Janney Montgomery Scott LLC (JMS) is a full-service financial services firm and registered broker/dealer headquartered in Philadelphia, Pennsylvania. The firm is a subsidiary of Independence Square Properties LLC, itself a subsidiary of Penn Mutual Insurance Co. Their ultimate parent is Harleysville Mutual Insurance Co. JMS is a member of the NYSE, the SIPC and FINRA. The firm provides comprehensive financial advice and services to individual, corporate and institutional investors. Their primary coverage verticals include the consumer, technology, financials and infrastructure sectors.

Inpellis, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing transdermal prescription therapeutics for treating acute and chronic pain resulting from musculoskeletal disorders and peripheral neuropathy. Its products include transdermal ibuprofen for moderate to severe osteoarthritis and transdermal benfotiamine for painful diabetic neuropathy. The company was founded in 2012 and is headquartered in Haddonfield, NJ.

Linnaeus Therapeutics, Inc. engages in identification and development of small molecule agents that modulate cellular differentiation for the treatment of cancer and disorders of pigmentation. The company was founded by Christopher Natale and Todd Ridky in 2016 and is headquartered in Haddonfield, NJ.

Linnaeus Therapeutics LLC is a development-stage biotech company that identifies and develops small molecule agents for the treatment of various cancers. The private company is based in Philadelphia, PA. The company's compounds can be used to increase or decrease pigmentation and provide a UV-protecting tan without DNA damage. The company was founded in 2016 by Christopher Natale, Todd Ridky, and the CEO is Patrick T. Mooney. The company also focuses on modulating melanocyte pigmentation to correct genetic and acquired skin pigmentation conditions.